blood products production from transgenic animals

25

Upload: rekha-lakshmi-narayanan

Post on 26-Dec-2014

52 views

Category:

Documents


5 download

TRANSCRIPT

Page 1: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 2: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Animal cell culture is used to produce variety of commercial & medicinal prods.

Evaluation of new drugs on culture cells is being done which is cost-effective and less time consuming.

Page 3: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Whole blood consists of RBC’s,WBC’s,platelets are suspended in fluid called plasma.

when blood is allowed to clot it forms cross-linked network known as serum.

Various comp of blood serve a wide range of physiological func.

Specific blood prtns that are of therapeutic use are:-

clotting factors Serum albumin.

fibrinolytic agents. Ig.

Page 4: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 5: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

T-PA is an enzyme produced by mammalian cells in small amts.

This removes blood clot and obstruction in blood vessels.

First prtn to be produced on a commercial scale.

GENETECH had cloned human T-PA for treating blood clots.

The trade name of this product is Activase.

Page 6: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 7: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Human mRNA coding for T-PA from human mylenoma cell line.

Reverse transcription converted to cDNA

Inserted to Chinese Hamster Cell lines

CHO cells excrete T-PA in medium

Isolation of T-PA

Page 8: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 9: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

blood loss must be stopped in case of injury in which blood vessels are damaged.ss

prtn fibrinogen fibrin. aggregation of platelets at site of injury stops blood flow

blood coagulation process is dependent on various clotting factors[factor I-XIII].

factor VIII prevents hemophilia.

Page 10: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

In hemophiliac patients blood keeps flowing out in case of injury.

In 1984,gene that controls production of F VIII was isolated.

This enabled research & development of genetically engineered clotting factor.

In 1992, 1st genetically engineered clotting factor was introduced under trade name RECOMBINATE & RE FACTO.

Page 11: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

In 1993, GENETECH produced 2nd clotting factor under trade name KOGENATE.

There are 4 other recombinant F VIII:- BIO GEN GENETIC

THERAPY BIO VECTOR IMMUNE

RESPONSE

Page 12: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 13: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

EPO is a glycoprtn hormone produced primarily by cells of kidney.

Regulates RBC production.Secondary amts of hormone is synthesized in liver of healthy adults.

Page 14: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 15: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

This sialoglycoprotein hormone consists of 165 amino acids that form a single polypeptide chain containing two intra-chain disulfide bonds (Cys7-161 and Cys29-33) and four potential glycosylation sites, three of which are N-linked (Asn24, Asn38 and Asn83) and one O-linked (Ser126) (1,2).

Page 16: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

The molecular mass of EPO is 30-34 kDa, but the molecular mass of the peptide chain is only about 18 kDa. Thus, about 40% of the glycosylated EPO molecule consists of carbohydrate, mostly in the form of N-linked complex-type glycans.

Page 17: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Recombinant human EPO (rhEPO) is produced commercially by the expression of EPO cDNA clones in eukaryotic cell lines, most commonly in Chinese hamster ovary or baby hamster kidney cells with CMV and EF-1 promoters.

Page 18: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Transgenic pig containing the the human EPO gene placed under EF 1 promoter was developed

F2 generation piglets was analysed for pres of rHu-EPO recovery of rHu- EPO two-step precipitation method for the recovery of the

recombinant human erythropoietin (rhEPO) ammonium sulfate and divalent metal ions yield was

82.1%

Page 19: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

rHu- EPO is used for variety of clinical situations

increased production of RBCs anemia in HIV patients. curing post operative anemia.

Page 20: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Albumin from plasma fractionation is generally considered to be a safe and effective product.

A number of factors makes recombinant albumin manufacture increasingly attractive. These factors are as follows:

The perceived risk of viral contamination in serum albumin

likelihood of reduced availability of recovered plasma in the future

price

Page 21: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

Major component of blood plasmaFluid balance b/w blood & tissuesRegulates transport of Amino acids, Fatty

acids and Hormones, Drugs and drug metabolites

The expression of human albumin in the milk of transgenic cows has been identified as the most promising approach.

Page 22: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

A mammary gland expression vector that contained the goat β-casein gene promoter, 5′upstream regulatory region, exons 1,2, intron 1 as well as the human serum albumin (hALB) mini-gene (including the full-long sequences of hALB cDNA and its intron 1).

Page 23: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS
Page 24: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS

In exhaustible & in expensive.

Free from infectious agents.

New blood prtns not available earlier .

Page 25: BLOOD PRODUCTS PRODUCTION FROM TRANSGENIC ANIMALS